Here we will take a look into some valuation metrics for Arrowhead Pharmaceuticals, Inc. NasdaqGS:ARWR shares.

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) has a Price to Book ratio of 12.534079. This ratio is calculated by dividing the current share price by the book value per share. Investors may use Price to Book to display how the market portrays the value of a stock. Checking in on some other ratios, the company has a Price to Cash Flow ratio of , and a current Price to Earnings ratio of -23.436824. The P/E ratio is one of the most common ratios used for figuring out whether a company is overvalued or undervalued.

There are plenty of various strategies to employ when deciding which stocks to buy. These different strategies may be super simple or highly complex. Although there is no one plan that will magically create instant profits, having a plan in place will most likely benefit the investor immensely. One way to examine shares is by following fundamental data. Essentially, fundamental study involves viewing the health of a particular company by studying company financials. Many investors will closely study the balance sheet to see how profitable the company has been and try to figure out future performance. Investors may choose to compare companies that share the same sector in order to get a truer sense of how it stacks up to the competition.

In taking a look at some additional key numbers, Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) has a current ERP5 Rank of 16992. The ERP5 Rank may assist investors with spotting companies that are undervalued. This ranking uses four ratios. These ratios are Earnings Yield, ROIC, Price to Book, and 5 year average ROIC. When looking at the ERP5 ranking, it is generally considered the lower the value, the better.

The Gross Margin Score is calculated by looking at the Gross Margin and the overall stability of the company over the course of 8 years.  The score is a number between one and one hundred (1 being best and 100 being the worst).  The Gross Margin Score of Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) is 1.00000.  The more stable the company, the lower the score.  If a company is less stable over the course of time, they will have a higher score.

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) currently has a Montier C-score of -1.00000. This indicator was developed by James Montier in an attempt to identify firms that were fixing the books in order to appear better on paper. The score ranges from zero to six where a 0 would indicate no evidence of book cooking, and a 6 would indicate a high likelihood. A C-score of -1 would indicate that there is not enough information available to calculate the score. Montier used six inputs in the calculation. These inputs included a growing difference between net income and cash flow from operations, increasing receivable days, growing day’s sales of inventory, increasing other current assets, decrease in depreciation relative to gross property plant and equipment, and high total asset growth.

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) has an M-score Beneish of -999.000000. This M-score model was developed by Messod Beneish in order to detect manipulation of financial statements. The score uses a combination of eight different variables. The specifics of the variables and formula can be found in the Beneish paper “The Detection of Earnings Manipulation”.

Investors might be searching far and wide for the next set of winning stocks to add to the portfolio. Many value investors may be on the lookout for stocks that are underpriced at current levels. Some investors may be looking for names that have the potential to see major growth in the next few years. Picking growth companies can be a bit riskier, but they may have much bigger potential for substantial returns. Other investors may be interested in finding companies that provide stable returns and pay out a solid dividend. Investors may even choose to piece together the portfolio with stocks from different categories. Having a diverse selection of stocks is typically recommended for longer-term portfolio health. 

The Value Composite One (VC1) is a method that investors use to determine a company’s value.  The VC1 of Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) is 87.  A company with a value of 0 is thought to be an undervalued company, while a company with a value of 100 is considered an overvalued company.  The VC1 is calculated using the price to book value, price to sales, EBITDA to EV, price to cash flow, and price to earnings.  Similarly, the Value Composite Two (VC2) is calculated with the same ratios, but adds the Shareholder Yield.  The Value Composite Two of Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) is 90.

At the time of writing, Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) has a Piotroski F-Score of 3. The F-Score may help discover companies with strengthening balance sheets. The score may also be used to spot the weak performers. Joseph Piotroski developed the F-Score which employs nine different variables based on the company financial statement. A single point is assigned to each test that a stock passes. Typically, a stock scoring an 8 or 9 would be seen as strong. On the other end, a stock with a score from 0-2 would be viewed as weak.

Valuation

Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) presently has a current ratio of 0.00. The current ratio, also known as the working capital ratio, is a liquidity ratio that displays the proportion of current assets of a business relative to the current liabilities. The ratio is simply calculated by dividing current liabilities by current assets. The ratio may be used to provide an idea of the ability of a certain company to pay back its liabilities with assets. Typically, the higher the current ratio the better, as the company may be more capable of paying back its obligations.

The Earnings to Price yield of Arrowhead Pharmaceuticals, Inc. NasdaqGS:ARWR is -0.042668.  This is calculated by taking the earnings per share and dividing it by the last closing share price.  This is one of the most popular methods investors use to evaluate a company’s financial performance.  Earnings Yield is calculated by taking the operating income or earnings before interest and taxes (EBIT) and dividing it by the Enterprise Value of the company.  The Earnings Yield for Arrowhead Pharmaceuticals, Inc. NasdaqGS:ARWR is -0.045282.  Earnings Yield helps investors measure the return on investment for a given company.  Similarly, the Earnings Yield Five Year Average is the five year average operating income or EBIT divided by the current enterprise value.  The Earnings Yield Five Year average for Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) is -0.045610.

Free Cash Flow Growth (FCF Growth) is the free cash flow of the current year minus the free cash flow from the previous year, divided by last year’s free cash flow.  The FCF Growth of Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) is 1.000000.  Free cash flow (FCF) is the cash produced by the company minus capital expenditure.  This cash is what a company uses to meet its financial obligations, such as making payments on debt or to pay out dividends.  The Free Cash Flow Score (FCF Score) is a helpful tool in calculating the free cash flow growth with free cash flow stability – this gives investors the overall quality of the free cash flow.  The FCF Score of Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) is 1.568879.  Experts say the higher the value, the better, as it means that the free cash flow is high, or the variability of free cash flow is low or both.

As investors gear up for the stretch run towards the end of the year, the focus will be on which way stock market momentum seems to be shifting. Investors may be taking note of various economic reports and keeping a close eye on global political news. There are many factors that can affect the price of a stock. Tracking the markets from different angles may help to put together the bigger investing picture. Investors may be wondering if they have missed the boat as stocks have cooled off a bit recently. It may be wise to remember that there are always plenty of market opportunities to take advantage of. Diving into the fray may not be necessary until all the boxes are ticked off on the investor’s checklist. 

Volatility

Stock volatility is a percentage that indicates whether a stock is a desirable purchase. Investors look at the Volatility 12m to determine if a company has a low volatility percentage or not over the course of a year. The Volatility 12m of Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) is 80.090100. This is calculated by taking weekly log normal returns and standard deviation of the share price over one year annualized. The lower the number, a company is thought to have low volatility. The Volatility 3m is a similar percentage determined by the daily log normal returns and standard deviation of the share price over 3 months. The Volatility 3m of Arrowhead Pharmaceuticals, Inc. (NasdaqGS:ARWR) is 95.491300. The Volatility 6m is the same, except measured over the course of six months. The Volatility 6m is 87.522400.

Often times, investors may become worried when the stock market is highly volatile. Being prepared for volatile situations can help ease the fears that come along with turbulence. Following a well-crafted plan might help ride out the ups and downs that are a normal part of dealing with the market. Investors should be prepared for market situations that provide ample opportunities. Although market downturns can be unsettling and cause panic, investors who are able to stay the course and keep calm may be able to spot good buying opportunities when the wider market is selling.